Moore Capital Management LP Has $13.89 Million Stock Holdings in AbbVie Inc. $ABBV

Moore Capital Management LP trimmed its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 40.0% in the third quarter, Holdings Channel.com reports. The firm owned 60,000 shares of the company’s stock after selling 40,000 shares during the quarter. Moore Capital Management LP’s holdings in AbbVie were worth $13,892,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of ABBV. Kinloch Capital LLC lifted its stake in AbbVie by 1.5% in the third quarter. Kinloch Capital LLC now owns 24,530 shares of the company’s stock valued at $5,680,000 after buying an additional 372 shares in the last quarter. Laird Norton Wetherby Wealth Management LLC increased its position in shares of AbbVie by 0.4% during the third quarter. Laird Norton Wetherby Wealth Management LLC now owns 44,878 shares of the company’s stock worth $10,391,000 after acquiring an additional 199 shares in the last quarter. Larson Financial Group LLC increased its position in shares of AbbVie by 8.2% during the third quarter. Larson Financial Group LLC now owns 26,256 shares of the company’s stock worth $6,079,000 after acquiring an additional 1,987 shares in the last quarter. Integrated Wealth Concepts LLC raised its holdings in shares of AbbVie by 8.4% during the third quarter. Integrated Wealth Concepts LLC now owns 60,063 shares of the company’s stock worth $13,907,000 after acquiring an additional 4,643 shares during the period. Finally, JPL Wealth Management LLC raised its holdings in shares of AbbVie by 2.5% during the third quarter. JPL Wealth Management LLC now owns 28,344 shares of the company’s stock worth $6,563,000 after acquiring an additional 679 shares during the period. 70.23% of the stock is currently owned by institutional investors and hedge funds.

AbbVie Stock Up 0.8%

NYSE:ABBV opened at $221.54 on Tuesday. AbbVie Inc. has a twelve month low of $164.39 and a twelve month high of $244.81. The firm has a market capitalization of $391.72 billion, a price-to-earnings ratio of 93.87, a price-to-earnings-growth ratio of 0.76 and a beta of 0.34. The stock’s 50 day moving average price is $224.35 and its two-hundred day moving average price is $224.89.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, beating the consensus estimate of $2.65 by $0.06. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The company had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. During the same quarter in the prior year, the firm posted $2.16 EPS. The firm’s revenue for the quarter was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be paid a $1.73 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a yield of 3.1%. AbbVie’s dividend payout ratio (DPR) is currently 293.22%.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. Guggenheim reaffirmed a “buy” rating on shares of AbbVie in a research note on Thursday. UBS Group dropped their price target on AbbVie from $240.00 to $230.00 and set a “neutral” rating on the stock in a research note on Thursday, February 5th. Evercore cut their price target on AbbVie from $232.00 to $228.00 and set an “outperform” rating on the stock in a report on Wednesday, February 4th. William Blair reaffirmed an “outperform” rating on shares of AbbVie in a research report on Monday, March 9th. Finally, Wall Street Zen upgraded AbbVie from a “buy” rating to a “strong-buy” rating in a report on Saturday, February 28th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat.com, AbbVie has an average rating of “Moderate Buy” and a consensus price target of $253.15.

Insider Transactions at AbbVie

In other news, SVP David Ryan Purdue sold 5,230 shares of the company’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the sale, the senior vice president directly owned 2,654 shares of the company’s stock, valued at approximately $619,868.24. This represents a 66.34% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Perry C. Siatis sold 22,381 shares of the firm’s stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the sale, the executive vice president owned 38,137 shares of the company’s stock, valued at $8,771,510. This trade represents a 36.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.08% of the company’s stock.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.